Dementia risk and prevention by targeting modifiable vascular risk factors
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
The incidence of dementia is expected to double in the next 20 years and will contribute to heavy social and economic burden. Dementia is caused by neuronal loss that leads to brain atrophy years before symptoms manifest. Currently, no cure exists and extensive efforts are being made to mitigate cognitive impairment in late life in order to reduce the burden on patients, caregivers, and society. The most common type of dementia, Alzheimer's disease (AD), and vascular dementia (VaD) often co‐exists in the brain and shares common, modifiable risk factors, which are targeted in numerous secondary prevention trials. There is a growing need for non‐pharmacological interventions and infrastructural support from governments to encourage psychosocial and behavioral interventions. Secondary prevention trials need to be redesigned based on the risk profile of individual subjects, which require the use of validated and standardized clinical, biological, and neuroimaging biomarkers. Multi‐domain approaches have been proposed in high‐risk populations that target optimal treatment; clinical trials need to recruit individuals at the highest risk of dementia before symptoms develop, thereby identifying an enriched disease group to test preventative and disease modifying strategies. The underlying aim should be to reduce microscopic brain tissue loss by modifying vascular and lifestyle risk factors over a relatively short period of time, thus optimizing the opportunity for preventing dementia in the future. Collaboration between international research groups is of key importance to the optimal use and allocation of existing resources, and the development of new techniques in preventing dementia. image This article is part of the Special Issue “Vascular Dementia”.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
MACMAHON, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90878-9 · Cited by 4,253 · cited 2×
“For example, hypertension has long been known to cause stroke (MacMahon et al. 1990), but hypertension in mid-life ranks as an important risk factor for late cognitive decline (Knopman et al.”
BackgroundGorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811 · cited 4×
“Just like MCI is a prodromal stage of AD, VCI can cause mild cognitive deficits that can affect multiple cognitive domains and eventually progress to AD/VaD (Gorelick et al. 2011).”
InfluentialNgandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 6×
“While the FINGER (Ngandu et al. 2015) and multidomain Alzheimer prevention trial (Vellas and Carrie 2014) studies found a reduction in the incidence of dementia, the preDIVA (Prevention of Dementia by Intensive Vascular care) (van Charante et al. 2016) trial failed to find an effect calling attention to several method…”
BackgroundInfluentialBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Cited by
Early-Stage Alzheimer’s Disease Prediction Using Machine Learning Models
Kavitha, C., Mani, V., Srividhya, S. R., Khalaf, O. I., & Tavera Romero, C. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.853294 · Cited by 373
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Zhu, H.-Y., Hong, F.-F., & Yang, S.-L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094540 · Cited by 84
Low vision and the risk of dementia: a nationwide population-based cohort study
Paik, J.-S., Ha, M., Jung, Y. H., Kim, G.-H., Han, K.-D., Kim, H.-S., Lim, D. H., & Na, K.-S. (2020) · Scientific Reports · doi:10.1038/s41598-020-66002-z · Cited by 54
Impact of cardiovascular hemodynamics on cognitive aging
Moore, E. E., & Jefferson, A. L. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.311909 · Cited by 49
Lyu, Y., Meng, Z., Hu, Y., Jiang, B., Yang, J., Chen, Y., Zhou, J., Li, M., & Wang, H. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1394932 · Cited by 42
Deep learning applications in vascular dementia using neuroimaging
Dong, C., & Hayashi, S. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000920 · Cited by 13
Cognitive Aging Revisited: A Cross-Sectional Analysis of the WAIS-5
Winter, E. L., Dale, B. A., Maharjan, S., Lando, C. R., Larsen, C. M., Courville, T., & Kaufman, A. S. (2025) · Journal of Intelligence · doi:10.3390/jintelligence13070085 · Cited by 5
Metadata
- Authors
- Tariq, S., & Barber, P. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2017-09-06
- Volume
- 144
- Issue
- 5
- Pages
- 565-581
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2736594305
- Cited by
- 136
- References
- 71
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.